E2 is commercializing the Hēlo® Thrombectomy Platform, designed with a patented dual-action mechanism that integrates aspiration with mechanical clot disruption to deliver large-bore performance through a small-profile catheter. The system is indicated for non-surgical removal of emboli and thrombi from pulmonary arteries and venous vasculature and supports injection, infusion, and aspiration during procedures. E2 describes the platform as intended to improve procedural efficiency and clinical performance as mechanical thrombectomy adoption grows. With the oversubscribed $80 million Series C, the company plans to scale its commercial organization and continue investments in research and operations. The company is backed by a syndicate including Gilde Healthcare, Norwest, Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, and M&L Healthcare Investments. New board members from the lead investors will join as the company advances commercialization.

Total raised

$137M

Funding rounds

3

Latest round

Series C

Latest activity

Apr 2026